Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global leader in osteoarthritis pain management and regenerative orthopedic solutions, leveraging proprietary hyaluronic acid technology to develop differentiated medical products. Founded in 1992, the company focuses on early intervention orthopedics with a mission to… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Anika Therapeutics, Inc. does
In the company’s own words
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global leader in osteoarthritis pain management and regenerative orthopedic solutions, leveraging proprietary hyaluronic acid technology to develop differentiated medical products. Founded in 1992, the company focuses on early intervention orthopedics with a mission to restore active living and redefine what is possible with hyaluronic acid-based innovations.
The company operates through two primary product portfolios. Its Osteoarthritis Pain Management segment includes Monovisc and Orthovisc, single- and multi-injection hyaluronic acid viscosupplement products indicated for knee pain relief, which have maintained market leadership positions since 2018. Cingal, a next-generation single-injection product combining cross-linked hyaluronic acid with a fast-acting steroid, is CE marked and sold in over 50 countries outside the United States, with the company actively pursuing FDA approval for the U.S. market. The Regenerative Solutions portfolio comprises Integrity, an FDA-cleared hyaluronic acid-based scaffold for rotator cuff and tendon repairs that launched in 2023 and has demonstrated strong adoption; Hyalofast, a resorbable scaffold for cartilage regeneration available internationally and under FDA review in the United States; and Tactoset, an injectable bone substitute for fracture repair and hardware fixation.
In the United States, Anika maintains a strategic partnership with Johnson & Johnson MedTech, which exclusively markets Monovisc and Orthovisc. The company employs a hybrid commercial model for its Regenerative Solutions portfolio, combining its direct sales team with a network of independent third-party distributors. Internationally, Anika distributes products through a worldwide network of commercial partners. The company also markets legacy non-orthopedic hyaluronic acid products including Hyvisc for equine joint dysfunction, Hyalobarrier for post-surgical adhesion prevention, and ophthalmic products Anikavisc and Nuvisc.
Anika manufactures all hyaluronic acid-based products at its facility in Bedford, Massachusetts, where it has developed significant expertise in viscous liquid processing and scaffold creation. In 2024 and 2025, the company executed a strategic refocus, divesting Arthrosurface Incorporated and Parcus Medical to concentrate on its core hyaluronic acid technology platforms. The company's website is www.anikatherapeutics.com.
Company details
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- Headquarters
- BEDFORD, MA
- Fiscal year end
- December
- CIK
- 898437
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Anika Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Anika Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Anika Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Anika Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Anika Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”